09:39 AM EST - BioVaxys Technology Corp. : Announced today that they have entered into a broad collaboration for the co-development, joint commercialization, and marketing of BioVaxys vaccines for ovarian cancer, cervical cancer, and human papilloma virus ("HPV"), and the right of first refusal for marketing by BioVaxys in the United States of Procare Health's vaginal gel product, Papilocare™ , the world's first and only product to prevent and treat HPV-dependent cervical lesions. Under the terms of the agreement, which was executed on February 9th , 2021, the companies will jointly conduct a Phase I Clinical Study of BVX-0918A in Spain, BioVaxys' autologous haptenized protein vaccine for late-stage ovarian cancer. BioVaxys Technology Corp.
shares C.BIOV are trading unchanged at $0.48.
